Revolution Medicines, Inc. Revolution Medicines, Inc.

Revolution Medicines, Inc.

RVMD

Hisse Senetlerindeki Sıralama #619
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Hisse Fiyatı
$182.91
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$39.20B
Değişim (1 gün)
2.78%
Değişim (1 yıl)
238.66%
Ülke
US
Ticaret Revolution Medicines, Inc. (RVMD)

Kategori

Healthcare
Revolution Medicines, Inc. (RVMD) için temettü verimi geçmişi
Revolution Medicines, Inc. (hisse sembolü: RVMD) temettü verimi (TTM) 2023-12-31 itibariyle: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Revolution Medicines, Inc. (RVMD) için 2017 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL